Revvity Inc vs SYSCO Corporation — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while SYSCO Corporation trades at $78.58 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 2.3× Revvity Inc's market cap, and SYSCO Corporation pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and SYSCO Corporation for 77 Days on average.
| RVTY | SYY | |
|---|---|---|
Market Cap | $16.98B | $38.47B |
Volume | 1,456,900 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $157.36 | $91.16 |
52-Week Low | $82.26 | $69.30 |
Typical Hold Time | 12 Days | 77 Days |
Enterprise Value | $19.30B | $51.65B |
Dividend Yield | 0.18% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Sysco Corporation (SYY) trades at $78.14, up 1.76% with neutral technical signals. The company maintains steady revenue growth reaching $81.37B in 2025, though net margins compressed to 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $0.55 dividend declaration. Technical indicators show mixed signals with RSI neutral at 49.4 and ADX suggesting weak trend direction. The stock trades below analyst consensus target of $85.75 with 60% buy ratings.
Sysco presents a balanced investment case with attractive valuation metrics (P/S 0.44) and strong institutional support, offset by margin pressure and elevated debt levels. The AI efficiency program targeting $500M savings by 2029 provides growth catalyst potential. Key risks include competitive pressures in food distribution and sensitivity to economic cycles affecting restaurant demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →